D
Verrica Pharmaceuticals Inc. VRCA
$7.79 $0.030.39% NASDAQ
Recommendation
Prev Close
$7.76
Volume
16,425
Avg Vol (90D)
342,241
Market Cap
$124.08M
Dividend & Yield
--
52-Week Range
$3.28 - $9.82
P/E (TTM)
--
EPS (TTM)
-$3.44
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Verrica Pharmaceuticals (VRCA, $7.76) Stochastic Oscillator left the oversold zone on January 21, 2026
1/22/2026 - Tickeron - Stocks
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint
1/21/2026 - TipRanks Financial Blog
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded at Wall Street Zen
1/20/2026 - Ticker Report
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update
1/18/2026 - MarketBeat
Verrica Pharmaceuticals (VRCA, $7.26) price may climb as it broke lower Bollinger Band on Jan 16, 2026
1/17/2026 - Tickeron - Stocks
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to "Buy" at Wall Street Zen
1/17/2026 - MarketBeat
Verrica Pharmaceuticals (VRCA, $8.02) Stochastic Oscillator left the oversold zone on January 12, 2026
1/13/2026 - Tickeron - Technical Analysis
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%
1/12/2026 - Zacks Investment Research
Verrica Pharmaceuticals (VRCA, $8.02) entered Downtrend as Momentum indicator drops below 0 level on Jan 08, 2026
1/9/2026 - Tickeron - Stocks
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Hold" by Brokerages
1/7/2026 - Ticker Report
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Hold" by Brokerages
1/7/2026 - MarketBeat
Verrica Pharmaceuticals (VRCA) Begins Phase 3 Trials for Common Warts Treatment
1/7/2026 - GuruFocus
Verrica announces first patient dosed in program evaluating YCANTH
1/7/2026 - TipRanks Financial Blog
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts
1/7/2026 - Globe Newswire
Verrica Pharmaceuticals (VRCA, $8.31) entered Downtrend as Momentum indicator drops below 0 level on Dec 31, 2025
1/1/2026 - Tickeron - Stocks
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Decreases By 26.2%
12/30/2025 - MarketBeat
Verrica Pharmaceuticals (VRCA, $8.16) entered Downtrend as Momentum indicator drops below 0 level on Dec 26, 2025
12/27/2025 - Tickeron - Stocks
Verrica Pharmaceuticals (VRCA, $8.11) entered Downtrend as Momentum indicator drops below 0 level on Dec 18, 2025
12/19/2025 - Tickeron - Stocks
Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Upgraded by Brookline Capital Management
12/18/2025 - MarketBeat
Verrica Pharmaceuticals (VRCA) Receives Upgrade from Brookline Capital VRCA Stock News
12/18/2025 - GuruFocus
Verrica Pharmaceuticals (VRCA, $8.05) Moving Average Convergence Divergence (MACD) Histogram turned negative on December 17, 2025
12/18/2025 - Tickeron - Stocks
Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline
12/18/2025 - TipRanks Financial Blog
Brookline gets more bullish on Verrica Pharmaceuticals, upgrades shares
12/18/2025 - The Fly
Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders
12/15/2025 - The Fly
Armistice Capital LLC Increases Stock Holdings in Verrica Pharmaceuticals Inc. $VRCA
12/12/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$30.83M
EBITDA (TTM)
-$15.76M
EBIT (TTM)
-$16.32M
Net Income (TTM)
-$26.01M
Balance Sheet
Total Assets (Q)
$40.90M
Total Debt (Q)
$35.74M
Total Liabilities (Q)
$57.94M
Book Value Per Share (Q)
-$1.80
Cash Flow
Cash from Operations (TTM)
-$29.10M
Cash from Investing (TTM)
$8.00K
Cash from Financing (TTM)
$27.23M
Net Change in Cash (TTM)
-$1.86M
Filings
Filing Date
Friday, November 14, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
3.32
7-Day Total Return
-2.87%
30-Day Total Return
-3.95%
60-Day Total Return
102.34%
90-Day Total Return
64.00%
Year to Date Total Return
-6.14%
1-Year Total Return
8.75%
2-Year Total Return
-86.64%
3-Year Total Return
-83.10%
5-Year Total Return
-93.84%
52-week Low
Nov 04, 2025 - $3.28
52-week High
Nov 28, 2025 - $9.82
Valuation
Market Cap
$124.08M - Micro Cap
Enterprise Value
$138.72M
Price/Sales (TTM)
2.39
Price/Book (Q)
-4.32
Dividends and Shares
Shares Outstanding
9.49M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.verrica.com
Phone Number
484 453 3300
Address
44 West Gay Street
West Chester, PA 19380
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product... more
NASDAQ 01/22/2026 12:44PM Eastern Quotes delayed